• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Panbela Therapeutics Inc (NQ: PBLA )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Mar 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Panbela Therapeutics Inc

    < Previous 1 2 3 Next >
    Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
    Developed in collaboration with Sanofi. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
    Trial's lower-than-expected event rate suggests improved survival outcomes 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Poster Presentation at American Association for Cancer Research:
    Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Transfer to OTCQB Market
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Secures ~$9M in Public Offering
    Via Investor Brand Network
    Panbela Announces Closing of Approximately $9.0 Million Public Offering
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Pricing of Approximately $9.0 Million Public Offering
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
    A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    PRISM Biotech in Motion: FDA Approval for Panbela Therapeutics Pediatric Cancer Drug; Shares Jump 120%
    Via AB Newswire
    Exposures Product Safety
    Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
    Patent developed in collaboration with Syngene International Ltd. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
    Patent developed in collaboration with Syngene International Ltd. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Present at the LD Micro Investor Conference
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
    Patent developed in collaboration with Sanofi 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
    Patent developed in collaboration with Syngene International Ltd. 
    From Panbela Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.